journal article·2018-01-02Open access

Microniosomes for concurrent doxorubicin and iron oxide nanoparticles loading; preparation, characterization and cytotoxicity studies

Behzad Behnam, Mohammad Rezazadehkermani, Saeid Ahmadzadeh, Ahad mokhtarzadeh, Seyed Noureddin Nematollahi-Mahani, Abbas Pardakhty

Abstract

The current work deals with developing a suitable drug delivery system of doxorubicin (DOX) for intraperitoneal chemotherapy using niosomes through formulating non-ionic surfactants consisting of Brij™ 52, span™ 60 and Solulan™ C24. Entrapping the magnetite nanoparticles in the hydrophilic parts of niosomes was accompanied with high-efficient DOX loading by the current novel remote-loading method. Cytotoxicity of the prepared formulations was evaluated in vitro against A549 and PC-12 cell lines using the colorimetric WST-1 assay test. The obtained results revealed that, the cytotoxicity of DOX increased up to 22% especially on A549 cells by the current delivery system.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · Nanoparticle-Based Drug Delivery · Microfluidic and Bio-sensing Technologies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran;

Department of General Surgery, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran;

Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran;

Department of Biotechnology, Higher Education Institute of Rab-Rashid, Tabriz, Iran;

Neuroscience Research Center, Kerman University of Medical Sciences, Kerman, Iran

Funding

Kerman Neuroscience Research Center

References (44)

Show source-provided references
1. 10.1208/s12248-015-9785-x10.1208/s12248-015-9785-x ↗
2. 10.3322/caac.2125410.3322/caac.21254 ↗
3. 10.1007/s11095-007-9298-010.1007/s11095-007-9298-0 ↗
4. 10.1007/s00595-014-0848-x10.1007/s00595-014-0848-x ↗
5. van Oudheusden TR · Anticancer Res · 2015 · 35 · 627
6. 10.1007/s11095-009-0031-z10.1007/s11095-009-0031-z ↗
7. 10.1517/17425247.2016.113448410.1517/17425247.2016.1134484 ↗
8. 10.1016/j.jconrel.2014.04.01510.1016/j.jconrel.2014.04.015 ↗
9. 10.1063/1.493568810.1063/1.4935688 ↗
10. 10.1002/ejic.20150059810.1002/ejic.201500598 ↗
11. 10.3109/21691401.2016.116770410.3109/21691401.2016.1167704 ↗
12. 10.1016/j.addr.2009.11.00210.1016/j.addr.2009.11.002 ↗
13. Shatalebi M · Res Pharmaceut Sci · 2010 · 5 · 107
14. 10.1080/1388020070121490410.1080/13880200701214904 ↗
15. 10.3109/1061186930899607010.3109/10611869308996070 ↗
16. 10.3109/1061186960899683110.3109/10611869608996831 ↗
17. 10.1111/j.2042-7158.1988.tb05263.x10.1111/j.2042-7158.1988.tb05263.x ↗
18. 10.3109/1061186940901590710.3109/10611869409015907 ↗
19. 10.3109/1083745090342652610.3109/10837450903426526 ↗
20. 10.1016/j.jconrel.2008.09.00510.1016/j.jconrel.2008.09.005 ↗
21. 10.1080/drd_10_4_25110.1080/drd_10_4_251 ↗
22. 10.1016/S0378-5173(00)00362-810.1016/S0378-5173(00)00362-8 ↗
23. 10.1201/978142002167710.1201/9781420021677 ↗
24. 10.1016/j.ijpharm.2006.08.00210.1016/j.ijpharm.2006.08.002 ↗
25. 10.1081/DDC-10010034810.1081/DDC-100100348 ↗
26. 10.1002/bdd.251015080710.1002/bdd.2510150807 ↗
27. 10.4103/0250-474X.2962210.4103/0250-474X.29622 ↗
28. 10.3109/1071754100370625710.3109/10717541003706257 ↗
29. 10.1124/jpet.108.14009510.1124/jpet.108.140095 ↗
30. 10.2217/fon.10.10010.2217/fon.10.100 ↗
31. Levi-Polyachenko NH. · TONMJ · 2011 · 1 · 1E
32. 10.1517/14656566.2011.54534610.1517/14656566.2011.545346 ↗
33. 10.1517/17425247.2013.79635910.1517/17425247.2013.796359 ↗
34. 10.1016/S0304-4157(97)00006-310.1016/S0304-4157(97)00006-3 ↗
35. 10.1023/B:PHAM.0000012156.65125.0110.1023/B:PHAM.0000012156.65125.01 ↗
36. 10.1016/S0378-5173(97)00141-510.1016/S0378-5173(97)00141-5 ↗
37. 10.1016/S0378-5173(96)04840-510.1016/S0378-5173(96)04840-5 ↗
38. 10.1007/s10439-005-9002-710.1007/s10439-005-9002-7 ↗
39. 10.1586/ecp.09.3910.1586/ecp.09.39 ↗
40. 10.1016/j.biomaterials.2010.02.06810.1016/j.biomaterials.2010.02.068 ↗
41. 10.1016/j.jconrel.2009.10.00210.1016/j.jconrel.2009.10.002 ↗
42. 10.1148/radiol.231102155910.1148/radiol.2311021559 ↗
43. 10.1016/j.colsurfb.2012.09.01910.1016/j.colsurfb.2012.09.019 ↗
44. 10.1002/jps.2124910.1002/jps.21249 ↗